DNA methylation profiling of gynaecological cancers and endometriosis

MeD-seq & MeD-scan, novel assay for genome-wide DNA methylation profiling in developing predictive biomarkers of gynaecological cancer and endometriosis - MeD-seq a novel assay for genome-wide DNA methylation

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON51586

Enrollment

250

Registered

2022-07-29

Start date

2022-12-12

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer, vulva cancer, ovarian cancer, uterine cancer and endometriosis

Interventions

Not applicable.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Gynaecological cancer or endometriosis patients>= 18 years undergoing gynaecological examination 2. Healthy women >= 18 years undergoing gynaecological surgery 3. Healthy women >= 18 years undergoing gynaecological examination 4. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Women not able to read or understand the PIF (patient information). 2. Women not willing to participate. 3. Other malignancies in the past 5 years, except for basal cell carcinoma of the skin

Design outcomes

Primary

Measure	Time frame
1. To develop a test for early detection of female genital cancer and endometriosis using vaginal self-swabs, Pap smears and blood. 2. The DNA methylation atlas of normal female genital cell types.	—

Secondary

Measure	Time frame
Development of a DNA methylation atlas of the healthy female genital cell types (vulva, vagina, cervix, uterus, tubes and ovaries) using the MeD-seq technology.	—

Countries

Netherlands

Contacts

Public ContactC. Berg

Erasmus MC, Universitair Medisch Centrum Rotterdam

c.vandenberg@erasmusmc.nl010-7040704

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)